Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$400.9MCash on Hand
52.6mo Cash Runway
Follow EVO by emailGet an email when EVO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EVO, unsubscribe in one click. Privacy
📣 What EVO Says Is Next
by 2028 · “MID-TERM FRAMEWORK 2026 - 2030 4 Group revenues are expected to grow to > €1 billion (8-12 % CAGR) 4 Adjusted EBITDA margin is expected to reach 20% by 2028 and exceed that level by 2030 3 INTERIM STATEMENT 3M 2026 FINANCIAL HIGHLIGHTS The following table provides an overview of the financial performance in the first three months of 2026 compared to the same period in 2025.”
Company press release, May 6, 2026 · SEC filing
by end of 2027 · “Horizon operating model transformation : Initiated with footprint reduction to 10 sites, establishment of Centers of Excellence and commercial leadership development; expected run-rate cost savings of ~€75 million by end of 2027 with first financial benefit visible 2H 2026”
Company press release, Apr 8, 2026 · SEC filing
fourth quarter · “For full-year 2025, Evotec expects results to fall within its previously communicated guidance ranges: · Group revenues of approximately €788 million at the high end of the €760-800 million guidance (€811 million at constant exchange rates (CER)) · Adjusted Group EBITDA of approximately €41 million versus guidance of €30-50 million (€52 million CER) Evotec will report final fourth quarter and full-year 2025 results on April 8, 2026.”
Company press release, Mar 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Earnings Group revenue fell 13.1% to €465.0m for the first nine months of 2026, above Q3 consensus expectations, with adjusted EBITDA of €(44.3)m and full-year 2026 guidance reaffirmed at €570–610m revenue. A CSO departure and a new CSO appointment were also announced. Form 6-K · SEC filing · Press release
Oct 15, 2026 ·
Leadership Evotec appointed Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026. She most recently served as Therapy Area Head at Novo Nordisk. The company also issued a voting rights notification on major holdings. Form 6-K · SEC filing · Press release
Oct 14, 2026 ·
Earnings Evotec reported preliminary unaudited nine-month 2026 revenues of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million, above market expectations, and reaffirmed full-year 2026 guidance. Full Q3 results follow November 5, 2026. Form 6-K · SEC filing · Press release
Sep 29, 2026 ·
Leadership Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026, by mutual consent with the company, which is searching for a successor. Form 6-K · SEC filing · Press release
Sep 9, 2026 ·
Clinical trial Evotec's subsidiary Just, Evotec Biologics started a Phase 1 trial of JST-018, an orthopoxvirus antibody cocktail, under a U.S. Department of War program. Two related contracts together have a potential value of up to $123.9 million. Form 6-K · SEC filing · Press release
Aug 13, 2026 ·
Earnings Evotec reported H1 2026 group revenue down 19.2% to €300.1m and adjusted group EBITDA of €(42.7)m, with FY 2026 revenue guidance of €570–610m and adjusted EBITDA guidance of €(70)–(105)m. It also placed €116.1m of convertible bonds. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2021 · N/A · Results Expected · Blood and Urine Sample Collection From Healthy Volunteers Registry primary completion date, not a results date
Mar 2009 · Phase 2 · Results Expected · Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation. Registry primary completion date, not a results date
May 2008 · Phase 2 · Results Expected · Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes Registry primary completion date, not a results date
Dec 2007 · Phase 1 · Results Expected · The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
EVO holds $400.9M in cash and short-term investments and burns about $22.8M/quarter from operations,
an estimated runway of 52.6 months at that rate (BioRadar estimate, not company guidance).
Share count 177,778,907 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full EVO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EVO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.